AC
QNRX

Armistice Capital’s Quoin Pharmaceuticals QNRX Stock Holding History

Armistice Capital’s Portfolio QNRX Stock Details QNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,143
Closed -$345K – 272
2024
Q4 		$345K Buy
+15,143
New +$348K ﹤0.01% 183

Other funds holding QNRX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Armistice Capital's QNRX Position: Q1 2025 in Review

Armistice Capital sold out of Quoin Pharmaceuticals (QNRX) in Q1 2025, closing a stake of 15,143 shares — an estimated $345K sold.

Armistice Capital first reported a position in QNRX in Q4 2024 and held it in 1 quarter. The position peaked at $345K in Q4 2024. 9 funds tracked by Wall St. Rank hold QNRX as of Q1 2025.

  • Armistice Capital reported no remaining Quoin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Armistice Capital sold 15,143 Quoin Pharmaceuticals shares in Q1 2025, an estimated $345K.
  • Armistice Capital first reported a position in Quoin Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Armistice Capital's Quoin Pharmaceuticals position peaked at $345K in Q4 2024.
  • 9 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q1 2025.

Based on Armistice Capital's 13F filing for Q1 2025, filed 15 May 2025.